Education
About Us
Working with TipRanks
Follow Us
Sumitomo Dainippon Pharma Co (JP:4506)
:4506
RESEARCH TOOLSreports
4506 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥279.00 - ¥993.00
Previous CloseN/A
Volume1.08M
Average Volume (3M)8.71M
Market Cap
¥363.13B
Enterprise Value¥672.02B
Total Cash (Recent Filing)¥85.39B
Total Debt (Recent Filing)¥374.42B
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Jul 30, 2025EPS Estimate
-2.35Last Dividend Ex-Date
Mar 30, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)6.08
Shares Outstanding397,900,150
10 Day Avg. Volume14,965,469
30 Day Avg. Volume8,708,869
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥850.09Price Target Upside-6.99% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Sumitomo Dainippon Pharma Co News
PremiumCompany Announcements
Sumitomo Pharma Unveils ‘Reboot 2027’ for Strategic Growth
PremiumCompany Announcements
Sumitomo Pharma Announces Significant Share Transfer in Asian Business
PremiumCompany Announcements
Sumitomo Pharma Proposes Amendments to Enhance Governance
PremiumCompany Announcements
Sumitomo Pharma Announces Reversal of Doubtful Accounts Allowance
PremiumCompany Announcements
Sumitomo Pharma Extends Executive Pay Cuts Amid Financial Challenges---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.40%
Mutual Funds
― Other Institutional Investors
95.96% Public Companies and
Individual Investors
4506 FAQ
What was Sumitomo Dainippon Pharma Co ’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co lowest stock price was ¥279.00 and its highest was ¥993.00 in the past 12 months.
What is Sumitomo Dainippon Pharma Co ’s market cap?
Sumitomo Dainippon Pharma Co ’s market cap is ¥363.13B.
When is Sumitomo Dainippon Pharma Co ’s upcoming earnings report date?
Sumitomo Dainippon Pharma Co ’s upcoming earnings report date is Jul 30, 2025 which is in 77 days.
How were Sumitomo Dainippon Pharma Co ’s earnings last quarter?
Sumitomo Dainippon Pharma Co released its earnings results on May 13, 2025. The company reported ¥6.08 earnings per share for the quarter, beating the consensus estimate of -¥12.32 by ¥18.4.
Is Sumitomo Dainippon Pharma Co overvalued?
According to Wall Street analysts Sumitomo Dainippon Pharma Co ’s price is currently Overvalued.
Does Sumitomo Dainippon Pharma Co pay dividends?
Sumitomo Dainippon Pharma Co pays a Annually dividend of ¥7 which represents an annual dividend yield of N/A. See more information on Sumitomo Dainippon Pharma Co dividends here
What is Sumitomo Dainippon Pharma Co ’s EPS estimate?
Sumitomo Dainippon Pharma Co ’s EPS estimate is -2.35.
How many shares outstanding does Sumitomo Dainippon Pharma Co have?
Sumitomo Dainippon Pharma Co has 397,900,150 shares outstanding.
What happened to Sumitomo Dainippon Pharma Co ’s price movement after its last earnings report?
Sumitomo Dainippon Pharma Co reported an EPS of ¥6.08 in its last earnings report, beating expectations of -¥12.32. Following the earnings report the stock price went up 2.694%.
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co ?
Currently, no hedge funds are holding shares in JP:4506
---
Company Description
Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
---
4506 Company Deck
---
4506 Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted promising developments in the oncology and regenerative medicine pipelines but was overshadowed by significant financial losses, decreased revenue across all segments, and underperformance of key products, leading to a revised downward financial forecast. The call focused on strategic adjustments to address market challenges and improve profitability.Read More>---
4506 Stock 12 Month Forecast
Average Price Target
¥850.09
▼(-6.99% Downside)
Technical Analysis
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Eisai Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
---